Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Panobinostat

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00742027Phase 2CompletedPrimary

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

NCT03655483Phase 2UnknownPrimary

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Showing all 2 trials

Research Network

Common Treatments

  • Panobinostat1
  • Gls0101

Active Sponsors

  • Novartis Pharmaceuticals1
  • Guangzhou Gloria Biosciences Co., Ltd.1

Top Investigators

Activity Timeline